Search results
Results from the WOW.Com Content Network
Genentech, Inc. is an American biotechnology corporation headquartered in South San Francisco, California, wholly owned by the Swiss multinational pharmaceutical company, the Roche Group. It became an independent subsidiary of Roche in 2009. Genentech Research and Early Development operates as an independent center within Roche. [6]
Main page; Contents; Current events; Random article; About Wikipedia; Contact us
Genentech developed the technique used to produce the first such insulin, Humulin, but did not commercially market the product themselves. Eli Lilly marketed Humulin in 1982. [28] Humulin was the first medication produced using modern genetic engineering techniques in which actual human DNA is inserted into a host cell (E. coli in this case ...
The Cabilly patents are two US patents issued to Genentech and City of Hope which relate to the "fundamental technology required for the artificial synthesis of antibody molecules." [ 1 ] The name refers to lead inventor Shmuel Cabilly, who was awarded the patent while working at City of Hope in the 1980s. [ 2 ]
Arthur Dale Riggs (August 8, 1939 – March 23, 2022) [1] was an American geneticist who worked with Genentech to express the first artificial gene in bacteria.His work was critical to the modern biotechnology industry because it was the first use of molecular techniques in commercial production of drugs [2] and enabled the large-scale manufacturing of protein drugs, including insulin.
Main page; Contents; Current events; Random article; About Wikipedia; Contact us
From a page move: This is a redirect from a page that has been moved (renamed).This page was kept as a redirect to avoid breaking links, both internal and external, that may have been made to the old page name.
Genentech prevailed during the reexamination of Cabilly II(2) by the USPTO (1). GlaxoSmithKline and Human Genome Sciences both are challenging the patent under antitrust law (1). This is based on the settlement between Genentech and Celltech and their dispute over the original Cabilly patent 4,816,567 and the Celltech's patent 4,816,397.